Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2024 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected...
January 09, 2024 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused...
January 04, 2024 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
January 04, 2024 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
December 12, 2023 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma...
December 12, 2023 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
November 28, 2023 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
November 20, 2023 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
November 01, 2023 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader CFT8634, a BRD9 Degrader, Will Not Advance in Synovial Sarcoma and...
October 11, 2023 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma

CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023 CFT7455 Monotherapy Phase 1 Dose Escalation Complete in...